Use your browser's back button to choose another title or click here for a New Search.



How to Get the Article

 Email CTN Library (free)

PubMed Central (free)

Journal subscriber access

 

Bookmark and Share

Predictors of Outcome for Short-Term Medically Supervised Opioid Withdrawal During a Randomized, Multicenter Trial of Buprenorphine-Naloxone and Clonidine in the NIDA Clinical Trials Network.

Drug and Alcohol Dependence 2009;99(1-3):28-36. [doi: 10.1016/j.drugalcdep.2008.06.016]

Douglas M. Ziedonis, MD, MPH (Robert Wood Johnson Medical Center, DV Node), Leslie Amass, PhD (Friends Research Institute, PR Node), Marc Steinberg, PhD (Robert Wood Johnson Medical School, DV Node), George E. Woody, MD (University of Pennsylvania, DV Node), Jonathan Krejci, PhD (Mercer Trenton Addiction Science Center, DV Node), Jeffrey J. Annon, MA (Integrated Substance Abuse Programs, UCLA, PR Node), Alan J. Cohen, MA, MFT (Bay Area Addiction Research and Treatment, PR Node), Nancy Waite-O'Brien, PhD (Betty Ford Center, PR Node), Susan M. Stein, MS, RPh (Wayne State University School of Medicine, GL Node), Dennis McCarty, PhD (Oregon Health & Science University, OR/HI Node), Malcolm S. Reid, PhD (NYU School of Medicine, NY Node), Lawrence S. Brown, Jr., MD, MPH (Addiction Research and Treatment Corporation, NY Node), Robert Maslansky, MD (New York University School of Medicine Bellevue Hospital, NY Node), Theresa M. Winhusen, PhD (University of Cincinnati/CinARC, OV Node), Dean Babcock, MSW (Midtown Community Health Center, OV Node), Gregory S. Brigham, PhD (Maryhaven, Inc, OV Node), Joan A. Muir, PhD (Center for Family Studies, U. of Miami, FL Node), Deborah Orr, PhD (Center for Drug-Free Living, FL Node), Betty J. Buchan, PhD (Operation PAR, Inc., FL Node), Terry Horton, MD (Phoenix House, LI Node), Walter Ling, MD (Integrated Substance Abuse Programs, UCLA, PR Node).

Few studies in community settings have evaluated predictors, mediators, and moderators of treatment success for medically supervised opioid withdrawal treatment. This report presents new findings about these factors from a study of 344 opioid-dependent men and women prospectively randomized to either buprenorphine–naloxone or clonidine in an open-label 13-day medically supervised withdrawal study (protocols CTN-0001 and CTN-0002, "Buprenorphine/Naloxone versus Clonidine for Inpatient/Outpatient Opiate Detoxification"). Subjects were either inpatient or outpatient in community treatment settings, but were not randomized by treatment setting. Medication type (buprenorphine–naloxone versus clonidine) was the single best predictor of treatment retention and treatment success, regardless of treatment setting. Compared to the outpatient setting, the inpatient setting was associated with higher abstinence rates but similar retention rates when adjusting for medication type. Early opioid withdrawal severity mediated the relationship between medication type and treatment outcome with buprenorphine–naloxone being superior to clonidine at relieving early withdrawal symptoms. Inpatient subjects on clonidine with lower withdrawal scores at baseline did better than those with higher withdrawal scores; inpatient subjects receiving buprenorphine–naloxone did better with higher withdrawal scores at baseline than those with lower withdrawal scores. No relationship was found between treatment outcome and age, gender, race, education, employment, marital status, legal problems, baseline depression, or length/severity of drug use. Tobacco use was associated with worse opioid treatment outcomes. Severe baseline anxiety symptoms doubled treatment success. Medication type (buprenorphine–naloxone) was the most important predictor of positive outcome; however the paper also considers other clinical and policy implications of other results, including that inpatient setting predicted better outcomes and moderated medication outcomes. (Article (Peer-Reviewed), PDF, English, 2008)

Keywords: Buprenorphine/Naloxone | Clonidine | Effectiveness trials | Opioid dependence| Opioid detoxification | Pharmacological therapy | Suboxone | Drug and Alcohol Dependence (journal)

Document No: 318, PMID: 18805656, PMCID: PMC2770269

Submitted by CTN Dissemination Librarians, 9/23/2008.

AUTHORS SEARCH LINK
Amass, Leslie search mail
Annon, Jeffrey J. search mail
Babcock, Dean search mail
Brigham, Gregory S. search mail
Brown, Lawrence S. Jr. search mail
Buchan, Betty J. search mail
Cohen, Allan J. search mail
Horton, Terry search
Krejci, Jonathan search mail
Ling, Walter search mail
Maslansky, Robert search mail
McCarty, Dennis search mail
Muir, Joan A. search mail
Orr, Deborah search mail
Reid, Malcolm S. search mail
Stein, Susan M. search
Steinberg, Marc search
Waite-O'Brien, Nancy search
Winhusen, Theresa M. search mail
Woody, George E. search mail
Ziedonis, Douglas M. search mail
PROTOCOLS
NIDA-CTN-0001 search www
NIDA-CTN-0002 search www
PARTICIPATING NODES
Pacific Region (Lead) search www
Delaware Valley search www
Florida Node Alliance search www
Great Lakes Regional search www
Greater New York (formerly Long Island and New York) search www
Ohio Valley search www
Western States (formerly Oregon/Hawaii) search www
Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 11/2009 -- http://ctndisseminationlibrary.org/display/318.htm
info@ctndisseminationlibrary.org